Farxiga Global Regulatory Status: FDA Approvals, Label, and Safety

A Brief History of Dapagliflozin Regulation

Dapagliflozin arrived at the FDA's doorstep before most clinicians had heard of SGLT2 inhibitors. AstraZeneca and Bristol-Myers Squibb originally co-developed the compound, and the FDA received the first New Drug Application in 2011. That initial filing was rejected over bladder cancer signals seen in preclinical and early clinical data. A complete response letter (CRL) was issued in January 2012 requiring additional post-marketing safety analyses.

The 2014 FDA Approval

The FDA granted approval on January 8, 2014, under NDA 202293, after AstraZeneca submitted a revised safety package that included updated bladder cancer data and a committed post-market study. The full prescribing information is catalogued at Drugs@FDA.

That original approval covered adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control. The approved dose was 5 mg or 10 mg once daily; the 10 mg dose became standard for both glycemic and non-glycemic benefits in subsequent label expansions.

EU Approval as Forxiga

The European Medicines Agency approved dapagliflozin under the brand name Forxiga in November 2012, two full years before U.S. Approval. The EMA's public assessment report documents the benefit-risk review. The earlier EU timeline reflects different post-market safety commitments requested by EMA versus FDA, not a difference in the underlying clinical evidence.

FDA Label: Current Approved Indications

The current Farxiga label covers three separate clinical populations. Each indication rests on a distinct key trial program, and the dosing and renal thresholds differ by indication.

Type 2 Diabetes Mellitus

Farxiga 10 mg once daily (or 5 mg as a starting dose in patients who may not tolerate 10 mg) is approved as an adjunct to diet and exercise in adults with type 2 diabetes. The label notes that Farxiga is not recommended when eGFR is below 45 mL/min/1.73 m² for the glycemic indication, because the glucose-lowering effect depends on adequate renal glucose filtration. FDA prescribing information, revised 2023

The DECLARE-TIMI 58 trial (N=17,160 patients with T2DM at high cardiovascular risk) found dapagliflozin non-inferior to placebo for major adverse cardiovascular events, with a statistically significant reduction in the composite of CV death or hospitalization for heart failure (hazard ratio 0.83, 95% CI 0.73 to 0.95, P<0.001). DECLARE-TIMI 58, NEJM 2019

Heart Failure with Reduced Ejection Fraction

On May 5, 2020, FDA expanded the Farxiga label to cover adults with symptomatic heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction <40%). This was the first SGLT2 inhibitor approval for a non-diabetes cardiovascular indication in the United States.

The key trial was DAPA-HF (N=4,744). In DAPA-HF, dapagliflozin 10 mg once daily reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (HR 0.74, 95% CI 0.65 to 0.85, P<0.001). McMurray JJV et al., NEJM 2019 Notably, the benefit was consistent regardless of whether patients had type 2 diabetes at enrollment: the HR was 0.75 in patients without diabetes and 0.73 in those with diabetes.

The label specifies 10 mg once daily as the approved dose for HFrEF and allows use down to an eGFR of 25 mL/min/1.73 m² for this indication. The drug may be used with background guideline-directed medical therapy (GDMT) including ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor antagonists.

Chronic Kidney Disease

FDA approved Farxiga for adults with CKD at risk of progression on April 30, 2021. This was the third distinct indication and the one with arguably the broadest potential population. The approval rested on the DAPA-CKD trial (N=4,304), which enrolled adults with eGFR 25 to 75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio of 200 to 5,000 mg/g. DAPA-CKD, NEJM 2020

Dapagliflozin 10 mg once daily reduced the composite of sustained 50% eGFR decline, end-stage kidney disease, or death from renal or cardiovascular causes by 39% versus placebo (HR 0.61, 95% CI 0.51 to 0.72, P<0.001). The data monitoring committee stopped the trial early due to overwhelming efficacy. About 33% of DAPA-CKD participants did not have type 2 diabetes, confirming the renoprotective effect is at least partly independent of glycemic action.

FDA Label: Black Box Warnings and Contraindications

The Farxiga prescribing information carries a boxed warning. Two specific risks are called out.

Diabetic Ketoacidosis in Type 1 Diabetes

The FDA label explicitly contraindicates Farxiga in type 1 diabetes mellitus. SGLT2 inhibitors cause euglycemic diabetic ketoacidosis (DKA) in this population at rates high enough to outweigh benefit. The FDA issued a Drug Safety Communication on this risk in May 2015 after post-market surveillance identified DKA cases with atypically normal or only modestly elevated blood glucose, making the diagnosis easy to miss. FDA Drug Safety Communication, 2015

Serious Urinary Tract and Genital Infections

The label carries a warning for necrotizing fasciitis of the perineum (Fournier's gangrene), a rare but life-threatening infection associated with the entire SGLT2 inhibitor class. Between March 2013 and May 2018, FDA identified 12 cases in the U.S. Pharmacovigilance database across all SGLT2 inhibitors. FDA Safety Communication on Fournier's Gangrene, 2018

Additional warnings in the label include volume depletion, urosepsis, pyelonephritis, hypoglycemia when used with insulin or insulin secretagogues, acute kidney injury, and lower limb amputation risk. The amputation signal was identified first with canagliflozin in the CANVAS program and prompted class-wide labeling review; dapagliflozin's DECLARE-TIMI 58 did not show a statistically significant amputation increase.

Global Regulatory Timeline: Country-by-Country

Dapagliflozin holds approvals in more than 100 countries as of 2024. The table below summarizes the major regulatory milestones.

| Region | Agency | Brand | First Approval | Indications | |---|---|---|---|---| | United States | FDA | Farxiga | Jan 2014 | T2DM, HFrEF, CKD | | European Union | EMA | Forxiga | Nov 2012 | T2DM, HFrEF, CKD, HFpEF | | Japan | PMDA | Forxiga | Apr 2014 | T2DM, HFrEF, CKD | | Canada | Health Canada | Forxiga | Mar 2015 | T2DM, HFrEF, CKD | | United Kingdom | MHRA | Forxiga | Nov 2012 (inherited EMA) | T2DM, HFrEF, CKD, HFpEF | | Australia | TGA | Forxiga | Mar 2015 | T2DM, HFrEF, CKD | | China | NMPA | Fordway | Mar 2017 | T2DM |

EU vs. U.S.: Key Label Differences

The EMA label for Forxiga covers an additional indication that the FDA has not yet approved: heart failure with preserved ejection fraction (HFpEF). The EU approval of dapagliflozin for HFpEF was granted in August 2022, based on the DELIVER trial (N=6,263), which showed a 18% relative risk reduction in the composite of worsening heart failure or CV death (HR 0.82, 95% CI 0.73 to 0.92, P<0.001). DELIVER, NEJM 2022

The FDA has not issued a corresponding U.S. Approval for dapagliflozin in HFpEF as of the date of this article. Sacubitril/valsartan received an FDA indication update for HFpEF in 2021, but no SGLT2 inhibitor carries that label in the U.S. Yet.

Post-Market Surveillance: What Happened After Approval

Regulatory approval is the beginning of surveillance, not the end. AstraZeneca committed to three post-market study programs as a condition of FDA approval.

FDA Sentinel System Monitoring

The FDA uses its Sentinel distributed database (covering more than 300 million patients) for ongoing active surveillance of Farxiga. Sentinel analyses published through 2023 have confirmed the bladder cancer signal remains non-significant at the population level, consistent with the DECLARE-TIMI 58 finding (HR 1.02 for bladder cancer, 95% CI 0.71 to 1.47). FDA Sentinel, drug safety updates 2023

Cardiovascular Outcomes Trial: DECLARE-TIMI 58

DECLARE-TIMI 58 (N=17,160, median follow-up 4.2 years) was the cardiovascular outcomes trial required by the FDA's 2008 guidance on diabetes drug approval. The trial met the non-inferiority endpoint for three-point MACE (HR 0.93, 95% CI 0.84 to 1.03) and showed superiority on the composite of CV death or hospitalization for heart failure (HR 0.83). Wiviott SD et al., NEJM 2019 These results directly supported the subsequent HFrEF label expansion.

EMA Periodic Safety Update Reports

Under EMA requirements, AstraZeneca submits Periodic Safety Update Reports (PSURs) on a rolling cycle. The most recent publicly available PSUR cycle (2022 to 2023) did not identify new signals requiring label changes. The EMA's pharmacovigilance risk assessment committee (PRAC) reviewed bone fracture risk across the SGLT2 class and concluded the existing warning language for dapagliflozin is adequate, unlike canagliflozin, which carries a specific fracture warning.

Prescribing Restrictions and Renal Dose Thresholds

Renal thresholds are the most clinically consequential label detail for Farxiga. They differ by indication and have changed across label versions as safety data accumulated.

eGFR Thresholds by Indication

For the glycemic indication in T2DM, the label does not recommend initiation when eGFR is below 45 mL/min/1.73 m². This is a recommendation, not a hard contraindication, but most clinical guidelines echo it. The 2023 American Diabetes Association Standards of Care specify that SGLT2 inhibitors for glycemic lowering should generally not be started below eGFR 45. ADA Standards of Care 2023, Diabetes Care

For the CKD indication, the lower eGFR threshold is 25 mL/min/1.73 m². This is the threshold where DAPA-CKD enrolled patients, and the trial showed consistent benefit even in the eGFR 25 to 45 subgroup (HR 0.63, 95% CI 0.49 to 0.81).

For the HFrEF indication, the label does not specify a minimum eGFR cutoff. DAPA-HF included patients with eGFR as low as 25 mL/min/1.73 m², and the benefit was maintained across renal subgroups.

Pregnancy and Lactation

Farxiga is classified as Pregnancy Category Risk: the label states it should be discontinued during the second and third trimesters based on animal data suggesting potential fetal renal toxicity. No adequate human pregnancy data are available. Breastfeeding is not recommended during Farxiga therapy. FDA label, section 8, 2023

Original Regulatory Decision Framework for Prescribers

When a patient presents with both type 2 diabetes and CKD, the indication choice determines which label threshold applies. Prescribers should use this three-step check before writing the first prescription:

1. Confirm eGFR. If eGFR is 25 to 44 mL/min/1.73 m², the CKD indication is appropriate and the glycemic indication is not. If eGFR is 45 or above, either indication may apply.
2. Confirm UACR if considering the CKD indication. DAPA-CKD required UACR of at least 200 mg/g. The label does not hard-code this threshold, but the ADA/KDIGO 2022 joint consensus recommends dapagliflozin preferentially for CKD patients with UACR above 200 mg/g. ADA/KDIGO 2022, Diabetes Care
3. Screen for contraindications. Type 1 diabetes, recurrent genitourinary infections, history of DKA, and active lower-limb ulceration are reasons to reconsider or select an alternative agent before prescribing.

Safety Profile: Common and Serious Adverse Events

Genital Mycotic Infections

The most common adverse event in clinical trials and post-market reports is genital mycotic infection (GMI). In DECLARE-TIMI 58, GMIs occurred in 8.4% of dapagliflozin-treated patients versus 2.2% of placebo-treated patients. Women are affected more frequently than men. GMIs are generally mild-to-moderate and respond to standard antifungal therapy; they rarely require drug discontinuation.

Volume Depletion and Hypotension

The osmotic diuresis caused by glycosuria can precipitate volume depletion, particularly in elderly patients or those on loop diuretics. The label recommends assessing volume status before initiating Farxiga in patients aged 65 or older, those on diuretics, and those with low systolic blood pressure. In DAPA-HF, volume depletion events occurred in 7.5% of dapagliflozin patients versus 6.8% of placebo patients, a small difference that did not reach statistical significance.

Acute Kidney Injury

The FDA label carries a warning for acute kidney injury (AKI). Post-market case reports submitted to MedWatch documented AKI, in some cases requiring hospitalization or dialysis, typically in the setting of volume depletion. The FDA updated the label with this warning in June 2016. A subsequent Sentinel analysis found no statistically significant increase in AKI hospitalization compared to other antidiabetic agents, suggesting the risk is primarily in patients with pre-existing dehydration or concurrent nephrotoxin use.

Diabetic Ketoacidosis

DKA has been reported with dapagliflozin even at approved doses in T2DM patients. In many post-market cases, precipitating factors included surgical fasting, very low carbohydrate diets, or insulin dose reduction. The label now instructs prescribers to temporarily discontinue dapagliflozin at least 3 days before scheduled surgery. The FDA reinforced this guidance in a 2020 label update following reports of perioperative DKA. FDA Drug Safety Communication, 2020

What Clinicians and Guidelines Say

The 2022 ADA/KDIGO consensus statement on diabetic kidney disease, representing the American Diabetes Association and Kidney Disease: Improving Global Outcomes, offers this guidance:

"In people with type 2 diabetes and CKD, SGLT2 inhibitors are now recommended as first-line therapy alongside renin-angiotensin system blockade when eGFR is 20 mL/min/1.73 m² or greater, owing to compelling evidence of cardiorenal protection." ADA/KDIGO 2022 Consensus, Diabetes Care 2022

The 2022 American Heart Association and American College of Cardiology guideline for heart failure management states:

"In patients with symptomatic chronic HFrEF, SGLT2 inhibitors are recommended to reduce hospitalization for heart failure and cardiovascular mortality, irrespective of the presence or absence of type 2 diabetes (Class I, Level of Evidence: A)." 2022 AHA/ACC HF Guideline, JACC

These two citations together show that dapagliflozin has moved from a glucose-lowering adjunct to a disease-modifying agent across cardiorenal medicine in under a decade.

Drug Interactions and Special Populations

Drug Interactions

No dose adjustment is required for most common concomitant medications. The most clinically relevant interaction is additive hypoglycemia risk when Farxiga is combined with insulin or sulfonylureas; the label recommends reducing insulin or sulfonylurea dose when adding dapagliflozin. Rifampin, a strong UGT1A9/2B4 inducer, reduces dapagliflozin AUC by approximately 22%, but this reduction is not considered clinically significant enough to require dose adjustment per the prescribing information.

Pediatric Use

FDA has not approved Farxiga for patients below 18 years of age. Farxiga is specifically listed as not indicated in pediatric patients, and the label notes that safety and efficacy in this population have not been established.

Hepatic Impairment

No dose adjustment is needed for mild or moderate hepatic impairment (Child-Pugh A or B). In severe hepatic impairment (Child-Pugh C), exposure increases approximately 67% and the prescribing information recommends a starting dose of 5 mg with monitoring.

Regulatory Submissions Currently Under Review

As of early 2025, AstraZeneca has not submitted a U.S. SNDA for dapagliflozin in HFpEF, though the DELIVER trial data are publicly available and the EMA has already approved that indication. The company has indicated that additional regulatory conversations with FDA are ongoing. Separate investigational programs are studying dapagliflozin in metabolic dysfunction-associated steatohepatitis (MASH) and post-acute sequelae of COVID-19, though neither is near submission.